Seviprotimut-L

Drug Profile

Seviprotimut-L

Alternative Names: Melanoma vaccine - Polynoma; POL-103A

Latest Information Update: 10 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polynoma
  • Developer New York University School of Medicine; Polynoma
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma

Most Recent Events

  • 22 May 2015 Phase-III is ongoing for Malignant melanoma in USA
  • 15 Sep 2013 Polynoma completes enrolment in the phase III MAVIS trial for Malignant melanoma in USA (NCT01546571)
  • 09 Apr 2012 Phase-III clinical trials in Malignant melanoma (late-stage disease) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top